Please use this identifier to cite or link to this item: https://doi.org/10.1186/s13223-021-00614-6
Title: Fexofenadine: review of safety, efficacy and unmet needs in children with allergic rhinitis
Authors: Meltzer, Eli O.
Rosario, Nelson Augusto
Van Bever, Hugo 
Lucio, Luiz
Keywords: Allergic rhinitis
Fexofenadine
Pediatrics
Quality of life
Second-generation antihistamines
Sedative effect
Issue Date: 2-Nov-2021
Publisher: BioMed Central Ltd
Citation: Meltzer, Eli O., Rosario, Nelson Augusto, Van Bever, Hugo, Lucio, Luiz (2021-11-02). Fexofenadine: review of safety, efficacy and unmet needs in children with allergic rhinitis. Allergy, Asthma and Clinical Immunology 17 (1) : 113. ScholarBank@NUS Repository. https://doi.org/10.1186/s13223-021-00614-6
Rights: Attribution 4.0 International
Abstract: Allergic rhinitis (AR) is the most common undiagnosed chronic condition in children. Moderate/severe AR symptoms significantly impair quality of life, and cause sleep disruption, absenteeism and decreased productivity. Additionally, untreated AR predisposes children to asthma and other chronic conditions. Although intranasal corticosteroids are the most effective pharmacologic treatment for AR, oral antihistamines are often preferred. First-generation antihistamines may be chosen to relieve AR symptoms as they are inexpensive and widely available; however, they cause sedative and cardiovascular negative effects due to poor receptor selectivity. Therefore, second-generation antihistamines were developed to reduce adverse effects while retaining efficacy. There are fewer clinical trials in children than adults, therefore, efficacy and safety data is limited, particularly in children under 6 years, highlighting the need to generate these data in young children with AR. Fexofenadine, a highly selective second-generation antihistamine, effectively alleviates symptoms of AR, is non-sedating due to decreased blood–brain barrier permeability, and is devoid of cardiovascular side effects. Importantly, fexofenadine relieves the ocular symptoms of allergic conjunctivitis, which occur concomitantly with AR, improving quality of life. Overall, fexofenadine displays a favorable safety profile and results in greater treatment satisfaction in children compared with other second-generation antihistamines. This review aimed to evaluate and compare the safety and efficacy of fexofenadine with other available first- and second-generation antihistamines in children with AR. © 2021, The Author(s).
Source Title: Allergy, Asthma and Clinical Immunology
URI: https://scholarbank.nus.edu.sg/handle/10635/233536
ISSN: 1710-1484
DOI: 10.1186/s13223-021-00614-6
Rights: Attribution 4.0 International
Appears in Collections:Elements
Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1186_s13223-021-00614-6.pdf946.02 kBAdobe PDF

OPEN

NoneView/Download

SCOPUSTM   
Citations

4
checked on Dec 2, 2022

Page view(s)

11
checked on Dec 1, 2022

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons